CytomX Therapeutics to Announce Fourth Quarter 2019 Financial Results
February 20 2020 - 8:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, plans to report fourth quarter
2019 financial results on Thursday, February 27, 2020, after the
close of U.S. markets. Following the announcement, the company will
host a conference call beginning at 5:00 p.m. ET to discuss its
results.
Participants may access the live audio webcast of the
teleconference from the “Investors & News” section of CytomX’s
website at http://ir.cytomx.com/. Please access the website 15
minutes prior to the start of the call to download and install any
necessary audio software.
Audio Conference Call:
|
U.S. Dial-in Number: |
(877) 809-6037 |
|
|
|
|
International Dial-in Number: |
(615) 247-0221 |
|
|
|
|
Conference ID: |
1686972 |
An archived webcast replay will be available on the Company's
website from February 27, 2020, until March 5, 2020.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical
company with a vision of transforming lives with safer, more
effective therapies. We are developing a novel class of
investigational antibody therapeutics, based on our Probody®
technology platform, for the treatment of cancer. As leaders in the
field, our innovative technology is designed to turn previously
undruggable targets into druggable targets and to enable more
effective combination therapies. CytomX and its partners, comprised
of leading biotechnology and pharmaceutical companies, have
developed a robust pipeline of potential best-in-class
immunotherapies against clinically validated targets and potential
first-in-class therapeutics against novel, difficult to drug
targets. Five novel drug-candidates utilizing our Probody
technology are in clinical trials, with three in Phase 2 studies
and two in Phase 1. These clinical programs include cancer
immunotherapies against validated targets such as a PD-L1-targeting
Probody therapeutic wholly owned by CytomX (CX-072) and a
CTLA-4-targeting Probody therapeutic partnered with Bristol Myers
Squibb (BMS-986249). The CytomX clinical stage pipeline also
includes first-in-class Probody drug conjugates against previously
undruggable targets, including a CD166-targeting Probody drug
conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting
Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and
CD71 are among cancer targets considered to be inaccessible to
conventional antibody drug conjugates due to their presence on many
healthy tissues. In addition to its wholly owned programs, CytomX
has strategic collaborations with AbbVie, Amgen and BMS. For
additional information about CytomX Therapeutics, visit
www.cytomx.com and follow us on LinkedIn and Twitter.
PROBODY is a registered trademark of CytomX Therapeutics.
Contact:
Investors and Media:
Christopher Keenan VP, Investor Relations and Corporate
Communications ckeenan@cytomx.com 650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2023 to Apr 2024